We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

49 hedge funds and large institutions have $128M invested in Sutro Biopharma in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

31% more capital invested

Capital invested by funds: $97.3M → $128M (+$30.2M)

14% more funds holding

Funds holding: 43 → 49 (+6)

0.17% more ownership

Funds ownership: 4.75% → 4.92% (+0.17%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
49
Holders Change
+6
Holders Change %
+13.95%
% of All Funds
1.06%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
8
Increased
16
Reduced
10
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
TCM
Tekla Capital Management
Massachusetts
+$4.28M
2
SCM
Sio Capital Management
New York
+$1.22M
3
State Street
State Street
Massachusetts
+$667K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$546K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$453K

Top Sellers

1
NC
Nexthera Capital
New York
-$2.25M
2
BlackRock
BlackRock
New York
-$978K
3
DCM
Driehaus Capital Management
Illinois
-$928K
4
OAM
Oxford Asset Management
United Kingdom
-$157K
5
Morgan Stanley
Morgan Stanley
New York
-$91.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
SHI
1
SV Health Investors
Massachusetts
$20.8M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$19.7M +$1.66K +16 +0%
EAM
3
Eventide Asset Management
Massachusetts
$13.8M – – –
SB
4
Samsara BioCapital
California
$12.8M – – –
VM
5
VV Manager
Massachusetts
$11.3M – – –
TCM
6
Tekla Capital Management
Massachusetts
$7.3M +$4.28M +41,137 +179%
CCM
7
Camber Capital Management
Massachusetts
$6.83M – – –
SFM
8
Sphera Funds Management
Israel
$4.99M +$312K +3,000 +7%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$4.56M -$3.64K -35 -0.1%
SCM
10
Sio Capital Management
New York
$4.54M +$1.22M +11,689 +41%
BlackRock
11
BlackRock
New York
$3.6M -$978K -9,404 -23%
DCM
12
Driehaus Capital Management
Illinois
$2.75M -$928K -8,918 -27%
Vanguard Group
13
Vanguard Group
Pennsylvania
$2.01M +$546K +5,249 +42%
IBT
14
International Biotechnology Trust
United Kingdom
$1.67M – – –
Jennison Associates
15
Jennison Associates
New York
$1.57M +$49.3K +474 +4%
PCM
16
Pentwater Capital Management
Florida
$1.45M +$262K +2,520 +25%
JP Morgan Chase
17
JP Morgan Chase
New York
$1.09M -$37.3K -359 -4%
State Street
18
State Street
Massachusetts
$995K +$667K +6,408 +275%
Northern Trust
19
Northern Trust
Illinois
$852K +$110K +1,055 +16%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$610K +$31.4K +302 +6%
Alyeska Investment Group
21
Alyeska Investment Group
Illinois
$571K +$1.56K +15 +0.3%
ACP
22
Acuta Capital Partners
California
$518K – – –
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
$496K +$453K +4,353 New
OAM
24
Oxford Asset Management
United Kingdom
$456K -$157K -1,506 -27%
Millennium Management
25
Millennium Management
New York
$429K +$392K +3,766 New
1
2 3

STRO Hedge Fund Activity: Q1 2019 in Review

49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2019, worth a combined $128M — up 31% from $97.3M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new STRO positions and 2 closed out — a net gain of 6 holders — while 16 added to existing stakes and 10 trimmed.

The largest buyer was Tekla Capital Management, adding an estimated $4.28M. The largest seller was Nexthera Capital, exiting entirely with an estimated $2.25M sold.

  • 49 institutional investors held Sutro Biopharma (STRO) as of Q1 2019, up from 43 in Q4 2018.
  • Funds reported $128M of Sutro Biopharma stock for Q1 2019, up 31% quarter-over-quarter.
  • 8 funds opened new Sutro Biopharma positions in Q1 2019 and 2 closed out, a net change of +6 holders.
  • The largest Sutro Biopharma buyer in Q1 2019 was Tekla Capital Management, an estimated $4.28M added.
  • The largest Sutro Biopharma seller in Q1 2019 was Nexthera Capital, an estimated $2.25M sold.

Based on aggregated 13F filings for Q1 2019.